Genexine Submits Paper on Clinical Study Results of COVID-19 DNA Vaccine

Genexine announced on May 12 that it has submitted the results of a clinical study demonstrating the effectiveness of its COVID-19 DNA vaccine (GLS-5310) administered intranasally (IN) and intradermally (ID) in preventing infection by the Omicron variant of COVID-19 to a renowned international academic journal.

The title of the submitted paper is "Prevention of Incidental COVID-19 (SARS-CoV-2) Infection by Intranasal (IN) and Intradermal (ID) Administration of the GLS-5310 DNA Vaccine During the Omicron Surge." A company representative stated, "The CoV2-008 clinical trial (NCT05182567) was not only the first clinical trial to administer a DNA vaccine intranasally (IN), but also the first clinical study to confirm the protective effect against new infections caused by the Omicron variant of COVID-19."

The representative added, "This clinical trial was designed to evaluate the safety and immunogenicity of the GLS-5310 DNA vaccine as a booster dose in individuals who had previously received either the Pfizer mRNA vaccine (BNT162b2), the Moderna mRNA vaccine (mRNA-1273), or the Janssen vaccine (Ad26.S.CoV2). The GLS-5310 DNA vaccine was administered intradermally (ID) using the GeneDerm device for inhalation, and when both intradermal (ID) and intranasal (IN) administration were performed, the intranasal (IN) dose was given using a nasal atomizer."

According to the company, the GLS-5310 booster DNA vaccine did not result in any serious adverse events related to the vaccine. Depending on the type of primary vaccine received, it increased binding antibody titers by 1.5 to 4 times and enhanced T-cell responses by up to 14 times.

Park Youngkeun, CEO of Genexine, stated, "For years, our company has led the development of vaccines for emerging infectious diseases using DNA platform-based technology. Just as with the GeneDerm device developed by our company, we will continue to develop innovative vaccine delivery solutions and new nucleic acid vaccines to respond to emerging infectious diseases."